203 results on '"Beeler, Judy"'
Search Results
2. Supplemental measles vaccine antibody response among HIV-infected and -uninfected children in Malawi after 1- and 2-dose primary measles vaccination schedules
3. Measles Humoral and Cell-Mediated Immunity in Children Aged 5—10 Years After Primary Measles Immunization Administered at 6 or 9 Months of Age
4. Immunogenicity, Immunologic Memory, and Safety Following Measles Revaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy
5. Increasing the Time of Exposure to Aerosol Measles Vaccine Elicits an Immune Response Equivalent to That Seen in 9-Month-Old Mexican Children Given the Same Dose Subcutaneously
6. Laboratory Characterization of Measles Virus Infection in Previously Vaccinated and Unvaccinated Individuals
7. Safety and Immunogenicity of Early Measles Vaccination in Children Born to HIV-Infected Mothers in the United States: Results of Pediatric AIDS Clinical Trials Group (PACTG) Protocol 225
8. Persistence of Vaccine-Induced Measles Antibody Beyond Age 12 Months: A Comparison of Response to One and Two Doses of Edmonston-Zagreb Measles Vaccine Among HIV-Infected and Uninfected Children in Malawi
9. Antibody Induced by Immunization with the Jeryl Lynn Mumps Vaccine Strain Effectively Neutralizes a Heterologous Wild-Type Mumps Virus Associated with a Large Outbreak
10. Immunogenicity of Standard-Titer Measles Vaccine in HIV-1-Infected and Uninfected Zambian Children: An Observational Study
11. Measles-Virus-Neutralizing Antibodies in Intravenous Immunoglobulins
12. Induction of Cellular and Humoral Immunity after Aerosol or Subcutaneous Administration of Edmonston-Zagreb Measles Vaccine as a Primary Dose to 12-Month-Old Children
13. The Mumps Virus Neurovirulence Safety Test in Rhesus Monkeys: A Comparison of Mumps Virus Strains
14. The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants
15. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination
16. Thrombocytopenia: Case definition and guidelines for collection, analysis, and presentation of immunization safety data
17. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children
18. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants
19. Antiproliferative action of interferon-α requires components of T-cell-receptor signalling
20. Evaluation of an Early Two-Dose Measles Vaccination Schedule
21. Human and Animal Viruses
22. Measles Maternal Antibodies With Low Avidity Do Not Interfere With the Establishment of Robust Quantity and Quality Antibody Responses After the Primary Dose of Measles, Mumps, and Rubella Vaccine Administered at 12-Months of Age
23. Development of a high-throughput assay to measure measles neutralizing antibodies
24. The effect of respiratory viruses on immunogenicity and protection induced by a candidate universal influenza vaccine in mice
25. Development of Luciferase Immunoprecipitation Systems (LIPS) Assay to Detect IgG Antibodies against Human Respiratory Syncytial Virus G-Glycoprotein
26. Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling
27. Measles vaccination and inflammatory bowel disease
28. Measles Maternal Antibodies With Low Avidity Do Not Interfere With the Establishment of Robust Quantity and Quality Antibody Responses After the Primary Dose of Measles, Mumps, and Rubella Vaccine Administered at 12-Months of Age.
29. Reactogenicity and Immunogenicity of a Quadrivalent Combined Meningococcal Polysaccharide Vaccine in Children
30. Human and Animal Viruses
31. Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop
32. Adverse Events After MMR or MMRV Vaccine in Infants Under Nine Months Old
33. Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins
34. Correction for Kim et al., Development of an Adenovirus-Based Respiratory Syncytial Virus Vaccine: Preclinical Evaluation of Efficacy, Immunogenicity, and Enhanced Disease in a Cotton Rat Model
35. Development of an Adenovirus-Based Respiratory Syncytial Virus Vaccine: Preclinical Evaluation of Efficacy, Immunogenicity, and Enhanced Disease in a Cotton Rat Model
36. Development of a Luciferase Immunoprecipitation System Assay To Detect IgG Antibodies against Human Respiratory Syncytial Virus Nucleoprotein
37. Mumps Vaccines
38. Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection
39. A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment
40. Influenza and respiratory syncytial virus (RSV) vaccines for infants: Safety, immunogenicity, and efficacy
41. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus.
42. Thrombocytopenia after vaccination: Case reports to the US Vaccine Adverse Event Reporting System, 1990–2008
43. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants
44. ELISA underestimates measles antibody seroprevalence in US military recruits
45. Identification of Linear Heparin-Binding Peptides Derived from Human Respiratory Syncytial Virus Fusion Glycoprotein That Inhibit Infectivity
46. Alpha and Lambda Interferon Together Mediate Suppression of CD4 T Cells Induced by Respiratory Syncytial Virus
47. RhoA-Derived Peptide Dimers Share Mechanistic Properties with Other Polyanionic Inhibitors of Respiratory Syncytial Virus (RSV), Including Disruption of Viral Attachment and Dependence on RSV G
48. Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine
49. STEVENS-JOHNSON SYNDROME AFTER VACCINATION
50. STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS AFTER VACCINATION: REPORTS TO THE VACCINE ADVERSE EVENT REPORTING SYSTEM
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.